Biotechnology
Antengene Announces Research Collaboration with Celularity to Evaluate the Potential Therapeutic Synergy of Combining Antengene's Best-in-Class Bispecific Antibody with Celularity's Natural Killer Cell Platform
- This research collaboration marks Antengene's entry into the field of cellular medicines. SHANGHAI and HONG KONGJuly 19, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discover...
WuXi AppTec Plans to Build a New Site in Singapore, Better Serving Global Partners and Advancing Healthcare Innovation
SINGAPORE, July 19, 2022 /PRNewswire/ -- WuXi AppTec, a leading global provider of R&D and manufacturing services that enable the global pharmaceutical and healthcare industry, today announced a plan to build a new R&D and manufacturing site inSingapore. The company intends to invest up to S$2 bi...
Guo Guangchang Visits Fosun's Member Companies in Hamburg, Germany and Meets Carola Veit, President of Hamburg Parliament
HONG KONG, July 19, 2022 /PRNewswire/ -- On 18 July 2022, Mr. Guo Guangchang, Chairman of Fosun International, and his delegation visited Yuyuan inHamburg, and German lifestyle fashion brandTom Tailor. He also met and had lunch with Ms. Carola Veit, President of the Hamburg Parliament. Mr. Marco W...
Brii Bio Announces Strategic Partnership with China Resources Pharmaceutical Commercial Group to Advance the Commercialization of Long-acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, in China
The partnership will accelerate stockpiling, channel distribution and hospital access for the amubarvimab/romlusevimab combination in China The amubarvimab/romlusevimab combination is the first locally-discovered and approved SARS-CoV-2 target-specific treatment inChina, evaluated through a rand...
llumina Among First in the World to Receive Approval of Science-Based Net-Zero Target
The Science Based Targets initiative has validated Illumina's targets to reach Net-Zero greenhouse gas emissions by 2050 SINGAPORE, July 19, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced today it is among the first g...
Significant Glycemic Control and Weight Loss: Innovent Announces Phase 2 Study of Mazdutide (IBI362) in Chinese Patients with Type 2 Diabetes Met Primary Endpoint
SAN FRANCISCO and SUZHOU, China, July 19, 2022 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and o...
I-Mab to Present Phase 2 Clinical Data of CD47 Antibody Lemzoparlimab at ESMO Congress 2022
GAITHERSBURG, Md. and SHANGHAI, July 18, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that an abstract reporting the latest clinical data fro...
OliPass Moves Forward to Second Stage of Phase 2a Trial for Pain Killer OLP-1002
SEOUL, South Korea, July 18, 2022 /PRNewswire/ -- OliPass Corporation, a South Korea based biotech specialized in the development of RNA therapeutics, announced to move forward to the second stage of the Phase 2a trial inAustralia in osteoarthritis (OA) patients for pain killer OLP-1002, an SCN9A...
Samsung Biologics to purchase land for its second Bio Campus
* Acquires additional land, sized 357,366㎡ valued at KRW 426 billion, for Bio Campus 2 * Plans to build Multi-Modal Plant, Open Innovation, and expanded manufacturing capacities INCHEON, South Korea, July 18, 2022 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), the world's leading contrac...
CStone Announces the NDA Approval of GAVRETO® (pralsetinib) for the Treatment of RET Fusion-Positive treatment-naïve (first-line) and pretreated Non-Small Cell Lung Cancer (NSCLC) in Hong Kong, China
* GAVRETO is the first highly selective rearranged during transfection (RET) inhibitor approved inHong Kong, China for the treatment of RET fusion-positive metastatic non-small cell lung cancer * GAVRETO is CStone's second therapy approved in Hong Kong, China * GAVRETO is CStone's ninth NDA ...
Lunit to be Listed on KOSDAQ next week
* Initial Public Offering of 1,215,800 shares of its common stock at KRW 30,000 * To be listed on the KOSDAQ market on July 21, 2022 SEOUL, South Korea, July 14, 2022 /PRNewswire/ -- Lunit, a global provider of AI-based cancer solutions, announced that it priced its initial public offering (I...
Merck Launches its Uptune Program in Asia for Collaborating with Startups
* Application period for the Merck Uptune program starts today * Topics vary from AI-enabled health and cell and gene therapy tools to innovative technologies and materials in semiconductor and smart manufacturing * Selected startups can receive funding of up to € 100,000 SHANGHAI, July 14, ...
Urgent support needed following the pandemic's effect on cancer screening services
Dry July call to arms will improve support for cancer patients SYDNEY, July 14, 2022 /PRNewswire/ -- Dry July Foundation is urging Australians to dig even deeper this Dry July to help people affected by cancer. So many Australians could not access vital lifesaving cancer screenings and treatment...
Nanoform and Pharmanovia to breathe new life into iconic medicines
HELSINKI, July 14, 2022 /PRNewswire/ -- Nanoform Finland Plc., an innovative nanoparticle medicine-enabling company, today announced that it has partnered with Pharmanovia, a fast-growing specialty pharma business with a portfolio of over 20 branded drugs in 140 markets. The new strategic partne...
GenScript ProBio and DAAN Bio Therapeutics, Sign a Strategic Cooperation MOU for the Discovery and Development of Novel Drugs
SEOUL, South Korea, July 14, 2022 /PRNewswire/ -- On the July 14, 2022, GenScript ProBio (Brian Ho-sung Min, CEO), a global CDMO, and DAAN Bio Therapeutics (Byoung Chul Cho, Co-Founder & CEO), an innovative new drug developer such as antibody treatments and cell therapy drugs, announced that the...
U.S. FDA Grants Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted for Individuals Aged 18 and Over
* Novavax' vaccine is the first protein-based COVID-19 vaccine authorized in the U.S. * Immunizations with the Novavax COVID-19 Vaccine, Adjuvanted as a primary series will begin upon product release and once a policy recommendation from the CDC is received GAITHERSBURG, Md., July 14, 2022 /P...
miR Scientific is proud to announce the commercial availability of the miR Sentinel™ Prostate Cancer Test
NEW YORK, July 14, 2022 /PRNewswire/ -- miR Scientific, LLC announces the miR Sentinel™ Prostate Cancer Test is now commercially available in the United States, Puerto Rico and select international markets. miR Sentinel™ is a novel, urine-based, molecular test that analyzes small non-coding RNA ...
Glenmark Pharmaceuticals and SaNOtize Announce Peer Reviewed Publication of Its Phase 3 Clinical Trials on SaNOtize's Novel Nitric Oxide Nasal Spray for COVID-19 in Lancet Journal
MUMBAI, India and VANCOUVER, BC, July 13, 2022 /PRNewswire/ -- Glenmark Pharmaceuticals Limited (Glenmark), an innovation-driven, global pharmaceutical company and SaNOtize Research and Development Corp, today announced thatThe Lancet Regional Health Southeast Asia (TLRHSEA) – peer reviewed, high...
Brii Biosciences Appoints Dr. Susannah Cantrell as Chief Business Officer
Strategic executive hire adds to Company's global leadership team and positions
the Company for continued growth
DURHAM, N.C.and BEIJING, July 13, 2022 /PRNewswire/ -- Brii Biosciences
Limited
Subang Jaya Medical Centre Applauded by Frost & Sullivan for Its Leadership Position in the Malaysian Hospital Industry
SJMC is well positioned to drive the private hospital space into its next growth phase, capturing market share and sustaining its leadership in the coming years. SAN ANTONIO, July 13, 2022 /PRNewswire/ -- Recently, Frost & Sullivan researched the Malaysian hospital industry and, based on its ana...
Week's Top Stories
Most Reposted
iKala Secures Over $20 Million in Series B+ Funding, Led by Chunghwa Telecom
[Picked up by 280 media titles]
2024-03-26 16:45Strengthening Interconnected Tourism Exchanges along the "21st Century Maritime Silk Road" Sanya Embarks on Tourism Marketing and Promotion Activities in Singapore
[Picked up by 276 media titles]
2024-03-22 21:46Chronicling ASEAN-China Friendship and Cooperation
[Picked up by 270 media titles]
2024-03-26 15:00Giti Tire Embarks on a Greener Future with New Chief Sustainability Officer
[Picked up by 263 media titles]
2024-03-25 09:00To jointly build equal, orderly multipolar world
[Picked up by 246 media titles]
2024-03-28 14:27